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AbstrAct
Lumbar puncture (LP) is an important and 
frequently performed invasive procedure for 
the diagnosis and management of neurological 
conditions. There is little in the neurological 
literature on the topic of periprocedural 
management of antithrombotics in patients 
undergoing LP. Current practice is therefore 
largely extrapolated from guidelines produced 
by anaesthetic bodies on neuraxial anaesthesia, 
haematology groups advising on periprocedural 
management of antiplatelet agents and 
anticoagulants, and by neuroradiology on 
imaging-guided spinal procedures. This paper 
summarises the existing literature on the 
topic and offers recommendations to guide 
periprocedural antithrombotic management 
for LP, based on the consolidation of the best 
available evidence.  
IntroductIon
Lumbar puncture (LP) is commonly used 
in neurology practice for diagnostic and 
therapeutic indications. In the context of 
an ageing population, increasing numbers 
of patients are prescribed regular anti-
platelet or anticoagulant medication 
(collectively known as antithrombotics), 
and/or have comorbid coagulopathies 
including thrombocytopenia, platelet 
dysfunction and coagulation factor defi-
ciencies. Herein, we present a review of 
existing literature relating to periproce-
dural management of antithrombotics 
in patients undergoing LP and draw 
recommendations from these for use in 
clinical practice, as well as highlighting 
other factors that should be considered 
when assessing a patient’s bleeding risk. 
We have also created an easy-to-follow 
visual summary (figure1).  An AGREE 
questionnaire relating to these guidelines 
has been completed and is available as an 
inline supplementary appendix (Supple-
mentary file 1).1 
current guIdAnce
Current guidance on the periprocedural 
management of antithrombotics for 
spinal procedures has mainly come from 
anaesthetic groups regarding neuraxial 
anaesthesia.2–4 The most recent guidelines 
were published by the European Society 
of Anaesthesiology (ESA),4 and the Amer-
ican Society of Regional Anesthesia and 
Pain Medicine (ASRA).3 In the UK, there 
is joint guidance from the Association of 
Anaesthetists of Great Britain and Ireland, 
the Obstetric Anaesthetists’ Association 
and Regional Anaesthesia UK.5 Only two 
guidance articles specifically relate to LP 
and antithrombotics: one in the Amer-
ican Journal of Neuroradiology regarding 
image-guided spinal procedures,6 and 
a recent review article in a Brazilian 
journal.7
There is guidance on perioperative 
management of anticoagulants and anti-
platelets recently released by the British 
Society of Haematology (BSH), and also 
previously from the American College of 
Chest Physicians.8 9 The BSH guideline 
expands on the 2011 guidance on the 
general management of warfarin.10 The 
BSH and National Institute for Health 
and Care Excellence provide guidelines 
on preoperative coagulation testing.11 12
rIsk versus benefIt
LP carries a risk of spinal haematoma 
and, rarely, intracranial haemorrhage.13 
14 The incidence of spinal haematoma 
following LP has not been reliably 
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estimated, but following epidural or spinal anaes-
thesia the reported incidence ranges from 1:1341 
to 1:200 000.4 15 16 A recent review identified 35 
cases of spinal haematoma following LP since 1974; 
this study found a significant correlation between 
pre-existing coagulopathy and poor neurological 
outcome (significant impairment, inability to ambu-
late without support and/or bowel/bladder dysfunc-
tion).13 The risk of haemorrhagic complications 
during spinal procedures rises with coagulopathy, 
increasing age, larger needle gauge, multiple needle 
insertions, existing vertebral column pathology, 
epidural rather than spinal anaesthetic and lumbar 
rather than thoracic epidural.3 4 16 17
The potential benefits of an LP must be weighed 
against the risk of bleeding. Even a small volume 
haematoma can potentially cause significant morbidity, 
unlike small volume bleeding at other anatomical sites. 
In addition, although the risk of spinal haematoma is 
low, it has an associated a large morbidity; in the case 
series of 35 patients, 43% were left with significant 
disability, and 23% died within 12 months.13 If the 
procedure is deemed necessary but there remains a 
high risk of bleeding, repeat traumatic attempts should 
be avoided, and one could consider using fluoroscopic 
guidance to reduce the risk of accidental injury to small 
blood vessels.18 Spinal haematoma should be suspected 
in anyone post-LP who develops progressive motor or 
sensory disturbance, and/or sphincter disturbance; it 
is frequently painless, and most present several days 
after the procedure, with complete paralysis then 
developing over 10–15 hours.3 19 All suspected cases 
should be promptly investigated with MRI,20 as the 
more rapidly any necessary neurosurgical intervention 
occurs, the better the outcome.19 21 Complete neuro-
logical recovery is unlikely if neurosurgical inter-
vention does not occur within 8 hours of symptom 
onset.3 Patients should be advised to seek emergency 
medical attention if they develop new neurological 
symptoms following LP.
Suspending antithrombotics also carries risk; usually 
of cardiac or cerebral ischaemia, or of venous throm-
boembolism. Therefore, the potential benefits of 
performing an LP must be weighed against the risk of 
temporary suspension of antithrombotic treatment. 
High-risk patients should have appropriate bridging 
treatment, discussed in more detail below; however, 
this is still not without increased risk of thrombosis. 
If a patient has a complex medical background, or has 
started anticoagulant or antiplatelet treatment within 
the past 12 months, then the procedure, and any 
periprocedural potential changes in antithrombotic 
medication, should be postponed pending a discus-
sion with the relevant specialty. Each patient should be 
considered on an individual basis, as there is likely to 
be several factors influencing the balance of risk and 
benefit.
coAgulopAthIes
thrombocytopenia
Guidance from the BSH suggests that a ‘safe’ platelet 
count for performing LP would be >40×109/L, and 
that those with a platelet count of 20–40×109/L be 
evaluated on an individual basis regarding the poten-
tial risk:benefit ratio.15 These recommendations do 
not take account of additional risk factors such as anti-
thrombotics, other coagulopathies, platelet dysfunc-
tion or situations in which the platelet count may fall 
rapidly between blood measurement and procedure. 
If an LP is required in an emergency in a patient with 
thrombocytopenia, or if the platelet count is not 
expected to recover independently within an accept-
able time period, then a platelet transfusion could 
be considered in selected patients; however, there is 
limited evidence to guide this,22 so discussion with the 
local haematology team is advised.
routine coagulation testing
Multiple guidelines concur that routine, unselected, 
coagulation testing is not required in those with a 
negative bleeding history and no liver disease.5 11 12 
23 Coagulation tests can be considered for patients 
with a history of bleeding, anticoagulant drugs, liver 
or renal failure, disseminated intravascular coagu-
lation, haematological disorders or inherited causes 
of coagulopathy.24 Note that coagulation test results 
do not correlate well with the risk of bleeding, and 
their utility is uncertain. We recommend discussion 
with a haematologist if the patient is considered at 
increased risk of bleeding for any reason, if there is a 
significant bleeding history, or if (should these tests are 
performed) an international normalised ratio (INR) or 
prothrombin time (PT) ratio is 1.5 or more, or the acti-
vated partial thromboplastin time (APTT) is prolonged 
above the reference range.
Inherited bleeding disorders
Management of patients with known inherited 
bleeding disorders—including Von Willebrand disease, 
haemophilia, inherited factor deficiencies and inher-
ited platelet function disorders—should be discussed 
with a haematologist for advice on specific manage-
ment. Similarly, discussion is needed for patients with 
a personal or family history of unexplained bleeding 
who have not previously been investigated.
recommendations
 ► Routine screening of coagulation and platelet count is 
not recommended in unselected patients.
 ► Coagulation tests can be considered for patients with 
a personal or family history of unexplained bleeding, 
currently on anticoagulant drugs, liver or renal failure, 
disseminated intravascular coagulation, haematological 
disorders or inherited causes of coagulopathy. The utility 
of these tests for predicting bleeding risk, however, is 
 o
n
 17 Septem
ber 2018 by guest. Protected by copyright.
http://pn.bmj.com/
Pract N
eurol: first published as 10.1136/practneurol-2017-001820 on 28 August 2018. Downloaded from
 
3Dodd KC, et al. Pract Neurol 2018;0:1–11. doi:10.1136/practneurol-2017-001820
Review
figure 1 Lumbar puncture (LP) and bleeding risk visual summary. AF, atrial fibrillation; APTT, activated partial thromboplastin time; 
DOAC, direct oral anticoagulant; INR, international normalised ratio; PT, prothrombin time; TIA, transient ischaemic attack; VTE, 
venous thromboembolism. 
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questionable, and a patient’s risk of haemorrhage should 
be considered on an individual basis.
 ► Any patient thought to be high risk for bleeding, or with 
a platelet count of <40×109/L, or a PT or APTT above 
the normal range, should have their treatment options 
discussed with the local haematology service, and be 
considered for postponing or avoiding the LP.
AntIcoAgulAnts
Warfarin
The BSH recommends withholding warfarin for 5 
days before minor procedures, and the ASRA recom-
mends withholding it for 4–5 days before neuraxial 
anaesthesia.3 10 The rate at which the INR falls, once 
warfarin is withheld, varies considerably between indi-
viduals; it will take longer for the INR to fall in the 
elderly, and in those with a higher initial INR; there-
fore, the INR should be checked on the day of the 
procedure.10 25 The BSH recommend an INR <1.5 
for minor procedures, and the ASRA recommend this 
threshold also for neuraxial anaesthesia,3 10 whereas 
the ESA recommend an INR ≤1.4 before spinal punc-
ture or regional anaesthesia.4 In patients who have 
recently stopped warfarin, a normal INR in the first 
1–3 days reflects the return of factor VII activity, but 
there still may not be full haemostasis due to factor 
II and X concentrations taking slightly longer to 
normalise.3
If an LP is required urgently, then one could consider 
giving intravenous vitamin K 5 mg to reverse the effects 
of warfarin, administered no <6–8 hours before the 
procedure. If more urgent reversal of warfarin is 
required then prothrombin complex concentrate 
should be used in addition to the vitamin K. Discussion 
with the local haematology service is advised before 
urgent reversal of warfarin.9 23 26 Following a proce-
dure, the ACCP advise restarting warfarin 12–24 hours 
after surgery, whereas the ESA advise that it can be 
restarted after catheter removal with neuraxial anaes-
thesia.4 9 The ACCP recommend prescribing double 
the patient’s usual maintenance dose for the first 
2 days when restarting, and this has been shown to be 
safe and effective,9 27 although many start the patient’s 
usual dose.
Interruption to oral anticoagulation is associated with 
an increased risk of thrombosis; this risk should be 
considered on an individual basis. A systematic review 
and a meta-analysis both found no proof for the efficacy 
of bridging to prevent thromboses, but with increased 
rates of bleeding.8 In patients with atrial fibrillation, 
the BRIDGE (Perioperative Bridging Anticoagulation 
in Patients with Atrial Fibrillation) trial showed that no 
bridging was non-inferior to bridging in terms of arte-
rial thromboembolism (p=0.01), with arterial thrombo-
embolism occurring in 0.4% of the no bridging group, 
and 0.3% of the bridging group.28 This trial, however, 
included few patients with CHADS2 scores≥5.
28 Note 
that the risk of death with bleeding is around 3%, whereas 
arterial thromboembolism is significantly more likely to 
cause severe disability (30%) or death (40%).10 The BSH 
encourage all patients to be considered on an individual 
basis, but advise that bridging therapy with treatment 
dose low-molecular-weight heparin (LMWH) should be 
considered in those that the thrombotic risk is especially 
high (table 1).28 Since the BRIDGE trial was performed, 
the CHA2DS2-VASc score has been validated as a better 
measure of risk for stroke in non-valvular atrial fibril-
lation than CHADS2, and therefore we would advise 
that the additional risk factors for thrombosis included 
in CHA2DS2-VASc score (prior myocardial infarction, 
peripheral arterial disease, aortic atheroma, age 65–74 
years and female sex) also be considered.29 Patients who 
have had a venous thromboembolism >3 months before 
can be given prophylactic LMWH as bridging therapy.8
Ideally, bridging therapy with treatment dose 
LMWH should be started once the patients' INR falls 
below their target range. In clinical practice, daily INR 
testing may not always be practical; one possible prag-
matic approach would be to start LMWH 36 hours 
after the last dose of warfarin, although there is no 
robust evidence to support this and so the risk-ben-
efit should be considered carefully on an individual 
basis.30 It should be stopped at least 24 hours before 
the procedure.8 10 For those on temporary anticoag-
ulation, for example, following a provoked venous 
thromboembolism, it should be considered whether it 
would be reasonable to delay the LP until after the 
period of anticoagulation has finished, or at least until 
after initial high risk period of 3 months.31
low-molecular-weight heparin
Significant anticoagulant activity is present for 
12 hours following administration of prophylactic 
dose LMWH (enoxaparin, tinzaparin, dalteparin) and 
for 24 hours following treatment dose, so LMWH 
should be withheld for these time periods before 
spinal puncture.3 4 6 32 Note that in severe renal failure 
Table 1 BSH guidance: patients with especially high thrombotic risk 
in whom to consider bridging with treatment-dose heparin
VTE Patients with a VTE within the previous 3 months.
Very high-risk patients such as patients with a previous 
VTE while on therapeutic anticoagulation who now have a 
target INR of 3.5.
AF Patients with a previous stroke/transient ischaemic attack in 
last 3 months.
Patients with a previous stroke/transient ischaemic attack 
and three or more of the following risk factors:
 ► Congestive heart failure;
 ► Hypertension (>140/90 mm Hg or on medication);
 ► Age>75 years;
 ► Diabetes mellitus.
MHV Mechanical heart valve patients other than those with a 
bileaflet aortic valve and no other risk factors.
AF, atrial fibrillation; BSH, British Society of Haematology; INR, 
international normalised ratio; MHV, mechanical heart valve; VTE, 
venous thromboembolism.
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the half-life of LMWH can be up to quadrupled, and 
therefore a longer time period of withholding should 
be considered.19
When is safe to restart LMWH is unclear; guidance 
ranges from 2 to 4 hours in the European guidelines 
(with an atraumatic procedure) to up to 24 hours in 
the American ones.2 6 33 The discrepancy between 
these two guidelines may well stem from the after-
math of a high number of spinal epidural haemato-
mata in the USA between 1993 and 1998 following 
the introduction of enoxaparin 30 mg twice a day for 
thromboprophylaxis, with no guidance on intervals 
between administration and neuraxial procedures; the 
incidence at the same time was much lower in Europe, 
where an enoxaparin 40 mg once-daily dosing regimen 
was mainly used.2 4 The UK obstetric guidelines for 
neuraxial anaesthesia advise 4 hours for prophylactic 
or treatment dose anaesthesia, with consideration 
to increasing this to 24 hours in the procedure was 
traumatic.5
fondaparinux
A single case of spinal haematoma has been reported 
with treatment-dose fondaparinux in neuraxial anaes-
thesia on initial dosing trials, but subsequently at 
prophylactic dose there were no further haemato-
mata in 3600 patients who had neuraxial anaesthesia; 
however, the catheters were removed 2 hours before 
starting treatment and patients were only included 
if the needle placement was atraumatic and inserted 
on first attempt.3 The ASRA guidelines suggest that 
prophylactic fondaparinux should be used only in 
these study conditions until further evidence is avail-
able.3 The EXPERT trial, however, included 1553 
patients who received neuraxial anaesthesia for 
orthopaedic surgery and started on fondaparinux 
2.5 mg once daily thromboprophylaxis afterwards.32 
They removed the catheter 36 hours after the last 
fondaparinux dose and then withheld the next dose 
for a further 12 hours, and reported no cases of spinal 
haematoma. Based on this, the European guidelines 
advocate stopping fondaparinux for 36–42 hours 
before the procedure, and for 6–12 hours afterwards.4 
There are no recommendations for withholding treat-
ment-dose fondaparinux (5–10 mg/24 hours); only 
that spinal puncture should be avoided due to the risk 
of accumulation.4
unfractionated heparin
Unfractionated heparin has a shorter half-life than 
LMWH (1–2 hours vs 3–7 hours). When given intra-
venously, spinal puncture should not be performed for 
2–4 hours after the last dose according to the ASRA, 
and not for 4–6 hours according to the ESA; the ASRA 
and UK guidelines also recommend that the patient 
should have a normal APTT ratio (≤1.4) before the 
procedure.3–5 Unfractionated heparin can be restarted 
1 hour after the procedure.3 4 33
direct oral anticoagulants
Recommendations on adjustment of treatment regi-
mens of the direct oral anticoagulants (DOACs) vary 
significantly between different advisory bodies; online 
Supplementary file 2 summarises the figures.3 5 7 30 
34–37 They are all partially renally excreted; therefore, 
the length of time for which they need to be with-
held before procedures depends on patients’ renal 
function. Standard coagulation tests such as the APTT 
and PT are not effective for monitoring DOACs. If 
an estimate of the anticoagulant effect of a DOAC is 
required before an LP, then drug-specific concentra-
tions can be measured, but routine testing of these 
before procedures is not necessary. Additionally, for 
dabigatran, a normal thrombin time and APTT indi-
cate there is very little anticoagulant effect.38 Idaru-
cizumab is a specific antibody-reversing agent for 
dabigatran, and can be used for emergency reversal 
of dabigatran. Andexanet-alfa is a reversal agent for 
rivaroxaban, apixaban and edoxaban, which is in clin-
ical trials and not available outside clinical trials in 
the UK at the time of writing.39 If urgent reversal of a 
DOAC is required, we recommend consultation with 
a haematologist.
Intravenous thrombolysis
Following intravenous thrombolysis, there is signif-
icant derangement in haemostasis for longer than 
24 hours, and the need for an LP should be carefully 
considered.6 19 In this situation it may help to measure 
the fibrinogen concentration, as this is one of the last 
clotting factors to recover following thrombolysis.3 6 
19 Thrombolysis is not recommended in the 10 days 
following puncture of non-compressible vessels.6 If 
thrombolysis were required in the 10 days following 
an LP then the risks and benefits would have to be 
considered on an individual basis. There is little or 
no evidence to enable any useful recommendations 
following administration of local (eg, intra-arterial or 
intravenous sinus) thrombolysis but there is unlikely 
to be any significant derangement of systemic haemo-
stasis beyond 24 hours.
recommendations
 ► Warfarin should be withheld for 5 days before an LP, 
and the INR, checked on the day of procedure, should 
be ≤1.4; warfarin can be restarted from 12 hours 
following the procedure.
 ► Patients at high risk for thrombosis should have bridging 
treatment dose LMWH, these include: patients with a 
venous thromboembolism within the previous 3 months, 
or previous venous thromboembolism while on thera-
peutic anticoagulation, those with mechanical heart 
valves other than those with a bileaflet aortic valve and 
no other risk factors, those with atrial fibrillation and 
previous stroke or transient ischaemic attack in the past 
3 months or previous stroke/transient ischaemic attack 
and CHA2 DS2-VASc score of ≥3.
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 ► Patients with venous thromboembolism >3 months 
earlier should receive prophylactic dose LMWH 
bridging.
 ► Ideally, bridging LMWH should be started once the 
patient’s INR falls below target range, which will be 
around 36 hours after the last dose of warfarin.
 ► Treatment dose LMWH should be withheld for 24 hours, 
and prophylactic dose for 12 hours before the proce-
dure. Both can be restarted 4 hours after LP if atrau-
matic; consider postponing treatment dose LMWH for 
24 hours if the procedure was traumatic.
 ► Prophylactic dose fondaparinux should be withheld for 
at least 36 hours before, and 6–12 hours after LP. LP 
should be avoided if possible in patients on treatment 
dose fondaparinux as there is little evidence around the 
bleeding risk, and concerns about accumulation. Intra-
venous unfractionated heparin should be withheld for 
4–6 hours before LP, and restarted 1 hour after LP.
 ► In patients with normal renal function (creatinine clear-
ance ≥50 mL/min), rivaroxaban and apixaban should 
be withheld for at least 24 hours before the procedure; 
dabigatran for at least 48 hours. The DOACs can be 
restarted 6 hours after LP.
 ► In emergency situations, warfarin and some DOACs 
can be reversed; this should be discussed with the local 
haematology team.
AntIplAtelets
Aspirin
Aspirin has not been shown to increase the risk of serious 
bleeding following minor procedures such as LP and so 
can be continued safely.2–4 19 A randomised controlled 
trial looking at the use of low-dose aspirin for pre-ec-
lampsia found no significant difference between the 
number of adverse events following epidural anaes-
thesia reported in those taking aspirin; haemorrhage 
occurred only in 1 of 1422 patients taking aspirin 
(53% continued to within 1 day of procedure), and 2 
of the 1361 allocated to placebo.40 Since then there 
have been further studies, including 193 orthopaedic 
patients undergoing spinal or epidural anaesthesia,40 
and 383 patients taking aspirin (158) or non-steroidal 
anti-inflammatories (NSAIDs), undergoing epidural 
corticosteroid injections; these showed no increase in 
minor (‘bloody tap’) or major haemorrhagic compli-
cations compared with patients not on aspirin or 
NSAIDs.17 High-dose aspirin is likely to produce a 
higher risk of bleeding, but there is little guidance 
with respect to time intervals for which this should be 
withheld.
Adp receptor antagonists (clopidogrel, ticagrelor, 
prasugrel)
There is less evidence quantifying the bleeding risk 
for ADP receptor antagonists with LPs. There are two 
previously reported cases of haemorrhagic complica-
tions of neuraxial puncture in patients on clopidogrel, 
although in both cases the patients were on multiple 
antiplatelet agents.41 42 The BSH guidelines state that 
there is insufficient evidence that they are safe in 
neuraxial anaesthesia and so advise that clopidogrel, 
ticagrelor and prasugrel are stopped 7 days before 
procedures.8 This is in agreement with both Amer-
ican and European anaesthetic guidelines that advise 
stopping clopidogrel for 7 days before neuraxial anaes-
thesia due to its irreversible effects on platelet activa-
tion, which last for the lifespan of the platelet.3 4 19
As with anticoagulation, one must weigh up the 
risk and benefit of withholding treatment. The risks 
from stopping antiplatelets is high in some patients, 
including those on drug-eluting coronary artery stents 
placed within the previous 12 months (especially the 
first 6 months), and bare metal coronary stents placed 
within the previous 1 month.43 The risk of stent throm-
bosis in these patients is high, and this carries a 50% 
risk of acute myocardial infarction or death43; there-
fore, if possible, LP should be delayed or avoided in 
these patients. Lower risk indications for ADP receptor 
antagonists include ischaemic heart disease without 
coronary stents, cerebrovascular disease, peripheral 
vascular disease, drug-eluting coronary stent placed 
over 12 months ago and bare metal coronary stents 
placed over 1 month ago.43 In these patients, while 
the ADP receptor antagonists is withheld, one should 
consider giving aspirin bridging, assuming no contra-
indication, to lessen the risk of thrombosis. If on dual 
antiplatelets, it is prudent to ensure that aspirin is 
continued.43
The ESA suggest that clopidogrel can be restarted 
immediately after catheter removal, and prasugrel 
and ticagrelor after 6 hours, in neuraxial anaesthesia, 
whereas the ASRA suggest withholding for a further 
24 hours.3 4 One could argue that 24 hours may be too 
long a window, unnecessarily increasing the throm-
bosis risk, whereas restarting immediately would pose 
difficulties if a spinal haematoma were to present in 
the first few hours following the procedure; in the 
absence of more concrete evidence, we recommend 
restarting these after 6 hours.
glycoprotein IIb/IIIa receptor antagonists
The risk of spinal haematoma associated with LP in 
patients taking these agents is unknown, but they 
have a profound effect on platelet aggregation as 
they block the final common pathway, and there is no 
available laboratory monitoring test.44 It is suggested 
that tirofiban and eptifibatide are withheld for at least 
4–8 hours before LP, and abciximab for 48 hours; after 
this time, normal platelet aggregation has usually been 
achieved.3 4 6 19 34 Note that in the British National 
Formulary, tirofiban is cautioned for use within 
24 hours of puncture of non-compressible vessels.45
other antiplatelets
Dipyridamole has a half-life of 10–12 hours; the only 
guidelines that mention it are the UK guidelines that 
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state that ‘no additional precautions’ are necessary, 
and that it can be restarted 6 hours after procedure.5 
Cilostazol, an arterial vasodilator that also inhibits 
platelet aggregation licensed for intermittent claudica-
tion should be withheld for 42 hours before a proce-
dure and for 5 hours after, according to the ESA.4
emergency reversal of antiplatelet drugs
There is no universally available reliable test to 
measure platelet function, and there is no proven 
effective reversal treatment in emergency situations. 
There is in vitro evidence that transfusion of two to 
three adult doses of platelets may reverse the effects 
of antiplatelet drugs,46 47 and limited evidence from a 
single arm clinical trial for patients taking dual anti-
platelet therapy before major non-cardiac surgery.48 A 
randomised trial comparing platelet transfusion with 
no platelet transfusion for reversal of antiplatelet drugs 
in intracerebral haemorrhage reported no improve-
ment in haemostasis and an increase in the combined 
end point of mortality and disability.49 Consequently, 
there is uncertainty about the efficacy of this approach 
before elective procedures. There is limited evidence 
in the setting or cardiac surgery that desmopressin 
might reduce the risk of bleeding for patients taking 
antiplatelet drugs.50 However, there is insufficient 
information to balance the risks and benefits of 
Table 2 Managing antithrombotics before lumbar puncture in patients with creatinine clearance ≥50 mL/min
Drug
Length of time to withhold before 
procedure Time to restart after procedure
Antiplatelets Aspirin Continue Continue
ADP receptor antagonists
  Clopidogrel, ticagrelor, prasugrel 7 days
Consider aspirin bridging
Avoid LP or liaise with cardiology if drug-
eluting stent <12 months or bare metal 
stent <1 months
6 hours
Glycoprotein IIa/IIIb receptor antagonists
  Tirofiban, eptifibatide 4–8 hours 24 hours
  Abciximab 48 hours 24 hours
Other antiplatelets
  Dipyridamole 24 hours 6 hours
  Cilostazol 42 hours 6 hours
Anticoagulation   Warfarin Target INR≤1.4
Elective: withhold for 5 days and then check 
INR the day of the procedure. If high risk for 
thrombosis* then use LMWH bridging
Urgent: liaise with haematology
12 hours
  LMWH prophylaxis 12 hours 4 hours
  LMWH treatment 24 hours 4 hours
24 hours if traumatic
  Fondaparinux prophylaxis 36 hours 6–12 hours
  Fondaparinux treatment Avoid LP Avoid LP
  Intravenous unfractionated heparin 4–6 hours
APTT ratio≤1.4
1 hour
Direct oral anticoagulants
  Rivaroxaban
  Up to 20 mg/day
24 hours 6 hours
  Apixaban
  5 mg/day
24 hours 6 hours
  Apixaban
  20 mg/day
24–48 hours 6–24 hours
  Dabigatran 150–300 mg/day 48–72 hours
Contraindicated according to manufacturer
6 hours
Contraindicated according to 
manufacturer
*High-risk conditions requiring treatment dose LMWH bridging: patients with a venous thromboembolism within the previous 3 months, or previous 
venous thromboembolism while on therapeutic anticoagulation, those with mechanical heart valves other than those with a bileaflet aortic valve 
and no other risk factors, those with atrial fibrillation and previous stroke or transient ischaemic attack in the past 3 months, or previous stroke/
transient ischaemic attack and CHA2DS2-VASc score of ≥3.
Intermediate-risk conditions requiring prophylactic dose LMWH bridging: venous thromboembolism>3 months ago.
APTT, activated partial thromboplastin time; INR, international normalised ratio; LMWH, low-molecular-weight heparin; LP, lumbar puncture.
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desmopressin for LP and on current evidence it cannot 
be recommended. Accordingly, reversal of antiplatelet 
drugs should not be considered as a matter of routine, 
but for high-risk procedures we recommend discussion 
with a haematologist about options for antiplatelet 
drug reversal.
If an anticoagulant or antiplatelet effect persists, 
haemostasis may be improved by the use of preopera-
tive parenteral tranexamic acid, which has been shown 
to reduce blood loss and transfusion requirements in 
both cardiac and trauma surgery, without increasing 
thrombotic complications.
recommendations
 ► Low-dose aspirin (75 mg once daily) does not need to be 
withheld prior to LP.
 ► Patients at very high risk for thrombosis if antiplatelets 
are stopped include those with drug-eluting coronary 
artery stents placed within the previous 12 months, and 
bare metal coronary stents placed within the previous 
1 month. In these patients, LP should be avoided or 
delayed, where possible, to avoid withholding the anti-
platelets in these high-risk periods. If the benefit of LP is 
felt to outweigh the risk of stopping antiplatelets, discuss 
with the relevant cardiology team.
 ► Patients at intermediate risk, for example, those on dual 
antiplatelets who do not fall in the very high risk cate-
gory above, or those with a complex cardiac history, 
should have their aspirin continued while their other 
antiplatelet is withheld, or consider aspirin bridging 
therapy in those not on it already.
 ► Clopidogrel, ticagrelor and prasugrel should be withheld 
for 7 days before LP, and can be restarted 6 hours after 
procedure.
 ► For emergency reversal of antiplatelet drugs, we recom-
mend discussion with a haematologist about the risks 
and benefits of using platelet transfusion (2–3 units).
dIscussIon
Current evidence and guidance on periprocedural 
management of antithrombotics in patients undergoing 
spinal procedures is primarily for neuraxial anaesthesia 
rather than LP. Some of the issues that need to be 
considered when comparing the risk:benefit ratio are 
complex, and have not been fully researched. Clini-
cians should be aware of these complexities, be vigi-
lant for both bleeding and thrombotic complications 
when performing LP, and act quickly if spinal haema-
toma is suspected. Guidance is variable, with American 
guidelines tending to be more cautious about bleeding 
risk than European guidelines.
Based on the available evidence, we have developed 
a summary of our recommendations for patients with 
normal renal function (creatinine clearance ≥50 mL/
min) (table 2), a bridging protocol for high-risk patients 
(table 3) and an easy-to-follow visual summary for use 
in clinical practice (figure 1). In general, our recommen-
dations follow British and European guidelines, which 
have been based on the known pharmacology of medi-
cations and expert consensus opinion rather than trial 
data.32 As a general principle, prior to an LP, medications 
should be withheld for twice their half-life.4
It is important to remember that withholding anti-
thrombotics for longer than required confers an increased 
risk of thrombosis that may be unjustified. Patients 
should always be considered on an individual basis and 
those thought to be at high risk for either bleeding or 
thrombosis should be discussed with the relevant local 
teams in haematology or cardiology, with careful consid-
eration as to whether the LP is truly indicated.
In some cases, LPs are required urgently: for example, 
in suspected subarachnoid haemorrhage, bacterial 
meningitis or viral encephalitis. In these cases, where a 
patient is on antithrombotic drugs that have not been 
stopped for the recommended period, the clinician 
must make a decision as to whether other diagnostic 
investigations would provide similar reliability. It may 
be felt that an LP is an urgent and necessary test; in 
these cases, again a discussion with haematology or 
cardiology teams may be helpful to safely reverse 
warfarin or some DOACs, or treat thrombocytopenia, 
as described above. There is limited evidence for 
periprocedural management of patients on irrevers-
ible agents such as clopidogrel, and with an unknown 
but likely rare risk of epidural haematoma; thus, a 
clinician may choose to proceed with an emergency 
LP, with consent from the patient, a careful approach 
to avoid traumatic tap and subsequent careful clinical 
observation.
Table 3 LMWH bridging protocol for high-risk patients
Days before/
after LP Warfarin Treatment dose LMWH
5 days before Do not take warfarin
4 days before Do not take warfarin Start treatment dose 
LMWH, check INR is 
below target range if 
possible
3 days before Do not take warfarin Give treatment dose 
LMWH
2 days before Do not take warfarin Give treatment dose 
LMWH
1 days before Do not take warfarin Hold LMWH for 24 hours 
before LP
Day of LP Do not take warfarin
Check INR≤1.4 before 
procedure
Take LWMH>4 hours 
after LP
1 day after Restart warfarin* Continue LMWH
2 days after Give warfarin* Continue LMWH
3 days after Dose according to INR Stop if/when INR is in the 
patient’s target range
*Warfarin can be restarted at the patient’s usual dose or double the 
usual dose.
INR, international normalised ratio; LMWH, low-molecular-weight 
heparin; LP,  lumbar puncture.
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There is still a lack of clarity on newer antithrom-
botics around the safe time periods to withhold 
before, and restart following, a spinal procedure. Due 
to the rarity of bleeding complications in LP, it will 
be impossible to provide definitive advice but updates 
to this guideline will be required as further evidence 
is acquired. Further agents are likely to appear over 
the coming years and the appropriate periprocedural 
management of these will also need to be established. It 
would also be beneficial to gain better data on the inci-
dence of spinal haematoma following LPs specifically, 
in order to aid neurologists to make more informed 
decisions when weighing up bleeding risk.
Key points
 ► A patient’s bleeding risk should be considered on an 
individual basis, based on personal and family history, 
comorbidities and medications.
 ► Patients with a high bleeding risk have an increased 
risk of spinal haematoma following lumbar puncture 
(LP).
 ► Routine screening of coagulation is not recommended 
on unselected patients, but those thought to be at 
high risk of bleeding should be discussed with the 
haematology team before the procedure.
 ► Low-dose aspirin (75 mg once daily) can be continued 
safely when performing LPs.
 ► Other antithrombotics should be withheld for 
appropriate periods before and after an LP to reduce 
the bleeding risk. Where an LP cannot be delayed, it 
is possible to reverse warfarin and some direct oral 
anticoagulants with an available antidote. If the agent 
is irreversible, such as clopidogrel, then an urgent LP 
must be considered carefully, as there is no evidence 
on the best management.
 ► When deciding to stop an antithrombotic medication 
to perform an LP, one must consider the increased 
risk of thrombosis that this confers. In patients at 
very high risk of thrombosis, the LP should be delayed 
or avoided, where possible. Patients at high risk of 
thrombosis in whom an LP is necessary should be 
given appropriate bridging treatment.
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